GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Debt-to-Equity

BRAIN Biotech AG (XTER:BNN) Debt-to-Equity : 0.23 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Debt-to-Equity?

BRAIN Biotech AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. BRAIN Biotech AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €4.28 Mil. BRAIN Biotech AG's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €18.41 Mil. BRAIN Biotech AG's debt to equity for the quarter that ended in Mar. 2024 was 0.23.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BRAIN Biotech AG's Debt-to-Equity or its related term are showing as below:

XTER:BNN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07   Med: 0.16   Max: 0.23
Current: 0.23

During the past 9 years, the highest Debt-to-Equity Ratio of BRAIN Biotech AG was 0.23. The lowest was 0.07. And the median was 0.16.

XTER:BNN's Debt-to-Equity is ranked better than
62.11% of 1391 companies
in the Chemicals industry
Industry Median: 0.36 vs XTER:BNN: 0.23

BRAIN Biotech AG Debt-to-Equity Historical Data

The historical data trend for BRAIN Biotech AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Debt-to-Equity Chart

BRAIN Biotech AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only - - 0.07 0.10 0.21

BRAIN Biotech AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.21 - 0.23

Competitive Comparison of BRAIN Biotech AG's Debt-to-Equity

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG's Debt-to-Equity Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Debt-to-Equity falls into.



BRAIN Biotech AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BRAIN Biotech AG's Debt to Equity Ratio for the fiscal year that ended in Sep. 2023 is calculated as

BRAIN Biotech AG's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BRAIN Biotech AG  (XTER:BNN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


BRAIN Biotech AG Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


BRAIN Biotech AG (XTER:BNN) Business Description

Traded in Other Exchanges
Address
Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Executives
Dr. Michael Majerus Supervisory Board
Dr. Georg Kellinghusen Supervisory Board
Michael Schneiders Board of Directors
Adriaan Moelker Board of Directors
Lukas Linnig Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines